10-Q: Regen Biopharma Reports Q2 2024 Financial Results, Cites Ongoing Losses and Need for Additional Financing

Regen Biopharma's Q2 2024 report reveals continued operating losses and a reliance on equity financing to sustain operations.

Summary

• Regen Biopharma reported a net loss of $122,473 for the quarter ended March 31, 2024, compared to a net loss of $54,978 for the same period in 2023.
• The company's operating loss for the quarter was $101,071, compared to $78,842 in the prior year.
• Revenues remained consistent at $59,065 for both the current and prior year quarter.
• For the six months ended March 31, 2024, the net loss was $472,233, compared to a net income of $1,580,752 for the same period in 2023, which was primarily due to a large derivative income.
• The company's cash balance decreased from $121,037 on September 30, 2023, to $78,115 on March 31, 2024.
• The company has current liabilities of $5,173,049 and states it will need additional financing to meet its cash requirements over the next twelve months.
• The company has been utilizing an equity line agreement with Coventry Enterprises to raise capital, selling 364,057 shares for $187,973 during the quarter ended March 31, 2024.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position with increasing losses, decreasing cash reserves, and a reliance on equity financing. The company's future is highly dependent on its ability to raise additional capital and successfully develop its products.

Positives

• Revenues remained consistent year-over-year at $59,065 for the quarter.
• The company has an equity line agreement in place to raise capital.

Negatives

• The company experienced a significant increase in net loss for the quarter and six month period.
• Cash reserves have decreased substantially.
• The company's investment securities have significantly decreased in value.
• The company has a substantial amount of current liabilities.
• The company states it will need additional financing to meet its cash requirements over the next twelve months.
• The company's operating loss increased for the quarter.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• The company has a history of net losses and may not achieve profitability.
• The company's reliance on equity financing may dilute existing shareholders.
• The company's intellectual property may not be successfully licensed or sold.
• The company is in the early stages of development and may not receive FDA approval for its products or therapies.

Future Outlook

The company states it will need additional financing to meet its cash requirements over the next twelve months and is relying on an equity line agreement to raise capital.

Management Comments

• The company's Principal Executive Officer and Principal Financial Officer have concluded that the company's disclosure controls and procedures are effective.
• The company's management believes that there were no changes to the company's internal controls over financial reporting that have been materially affected.

Industry Context

Regen Biopharma is a small biotechnology company focused on developing regenerative medical applications, a sector known for high risk and high potential reward. The company's financial results are typical of early-stage biotech companies that are heavily reliant on external funding and have yet to generate significant revenue from product sales.

Comparison to Industry Standards

• Regen Biopharma's financial performance is consistent with other early-stage biotechnology companies that are pre-revenue and heavily reliant on external funding.
• The company's reliance on equity financing is a common practice for biotech companies in the development phase.
• The significant decrease in the value of investment securities is not uncommon for companies holding shares in other early-stage ventures.
• The company's high operating losses are typical for companies that are investing heavily in research and development.
• Compared to larger, more established biotech companies, Regen Biopharma's financial position is significantly weaker, with limited cash reserves and substantial liabilities.

Related Party Transactions

• The company has related party transactions with Zander Therapeutics, Inc., including licensing agreements and investment securities.
• The company has related party transactions with David Koos, including notes payable and a sublease agreement.
• The company has related party transactions with Dr. Brian Koos, including payments for services.

Stakeholder Impact

• Shareholders face the risk of further dilution due to the company's reliance on equity financing.
• Employees may be impacted by the company's financial instability.
• Customers and suppliers may be impacted by the company's ability to continue operations.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company will need to secure additional financing to continue operations.
• The company will continue to develop its regenerative medical applications.
• The company will continue to seek FDA approval for its products and therapies.

Key Dates

Keywords

Regen Biopharma, Financial Results, Quarterly Report, Net Loss, Equity Financing, Biotechnology, NR2F6, Coventry Enterprises, Convertible Notes, Operating Loss